MedTrace Logo

A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping

NCT07164703 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2025-09-10

No results posted yet for this study

Summary

This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.

Conditions

  • Advanced Cholangiocarcinoma (Part 1)

Interventions

DRUG

Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.

Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.

Sponsors & Collaborators

  • Mao-Lin Yan

    lead OTHER

Principal Investigators

  • Maolin Lin, Doctor · Department of Hepatobiliary and Pancreatic Surgery, Affiliated Provincial Hospital of Fuzhou University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2029-10-01
Completion
2029-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07164703 on ClinicalTrials.gov